- Home
- CTMX vs ABL Comparison
CTMX vs ABL Comparison
Compare CTMX & ABL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- ABL
- Stock Information
- Founded
- CTMX 2008
- ABL 2004
- Country
- CTMX United States
- ABL United States
- Employees
- CTMX N/A
- ABL N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- ABL Investment Managers
- Sector
- CTMX Health Care
- ABL Finance
- Exchange
- CTMX Nasdaq
- ABL Nasdaq
- Market Cap
- CTMX 444.3M
- ABL 521.6M
- IPO Year
- CTMX 2015
- ABL N/A
- Fundamental
- Price
- CTMX $2.40
- ABL $5.25
- Analyst Decision
- CTMX Strong Buy
- ABL Strong Buy
- Analyst Count
- CTMX 2
- ABL 4
- Target Price
- CTMX $5.00
- ABL $13.13
- AVG Volume (30 Days)
- CTMX 1.5M
- ABL 808.3K
- Earning Date
- CTMX 08-07-2025
- ABL 08-07-2025
- Dividend Yield
- CTMX N/A
- ABL N/A
- EPS Growth
- CTMX 128.27
- ABL N/A
- EPS
- CTMX 0.49
- ABL N/A
- Revenue
- CTMX $147,557,000.00
- ABL $134,575,948.00
- Revenue This Year
- CTMX N/A
- ABL $68.84
- Revenue Next Year
- CTMX N/A
- ABL $26.84
- P/E Ratio
- CTMX $4.97
- ABL N/A
- Revenue Growth
- CTMX 23.81
- ABL 73.39
- 52 Week Low
- CTMX $0.40
- ABL $4.60
- 52 Week High
- CTMX $3.10
- ABL $11.86
- Technical
- Relative Strength Index (RSI)
- CTMX 51.91
- ABL 44.04
- Support Level
- CTMX $2.32
- ABL $4.96
- Resistance Level
- CTMX $2.47
- ABL $5.49
- Average True Range (ATR)
- CTMX 0.14
- ABL 0.20
- MACD
- CTMX -0.01
- ABL 0.11
- Stochastic Oscillator
- CTMX 17.89
- ABL 62.07
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About ABL Abacus Life Inc.
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company organizes its business into five reportable segments Active Management, Originations, Asset Management, Portfolio Servicing, and Technology Services. Its operations are confined to the United States.